Athanor Capital’s Acceleron Pharma XLRN Stock Holding History

Athanor Capital’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-4,264	Closed	-$406K	–	713
2020 Q2	$406K	Buy	+4,264	New	+$411K	0.02%	346

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Athanor Capital's XLRN Position: Q3 2020 in Review

Athanor Capital sold out of Acceleron Pharma (XLRN) in Q3 2020, closing a stake of 4,264 shares — an estimated $406K sold.

Athanor Capital first reported a position in XLRN in Q2 2020 and held it in 1 quarter. The position peaked at $406K in Q2 2020. 238 funds tracked by Wall St. Rank hold XLRN as of Q3 2020.

Athanor Capital reported no remaining Acceleron Pharma position as of Q3 2020 after selling out during the quarter.
Athanor Capital sold 4,264 Acceleron Pharma shares in Q3 2020, an estimated $406K.
Athanor Capital first reported a position in Acceleron Pharma in Q2 2020 and held it in 1 quarter.
Athanor Capital's Acceleron Pharma position peaked at $406K in Q2 2020.
238 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2020.

Based on Athanor Capital's 13F filing for Q3 2020, filed 16 Nov 2020.